ID: h-SDA-2026-04-26-gap-debate-20260417-033
Hypothesis
Neurogranin Co-Normalization Validates p-tau217 as a Surrogate for Synaptic Health Cessation
CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds. Ng reflects synaptic integrity while p-tau217 reflects neuronal injury—both must normalize to ensure treatment cessation occurs after the critical window of ongoing amyloid-induced synaptotoxicity has closed. However, neurogranin normalizes more slowly than p-tau217, making binary co-normalization requirement impractical; instead, a composite synaptic-health score should replace the binary requirement.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SNAP25/Synaptosomal-Associated Protein<br/>SNARE Complex Member"]
B["VAMP2 and STX1A Complex Assembly<br/>Synaptic Vesicle Docking"]
C["Neurotransmitter Release<br/>Synaptic Vesicle Fusion and Exocytosis"]
D["Tau Sequestration<br/>VAMP2 Availability Reduced"]
E["SNAP25-Tau Interaction<br/>Exocytotic Machinery Impairment"]
F["SNAP25 Disruption<br/>Synaptic Vesicle Tau Capture and Neurotransmission Failure"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports4 contradicts
Supports
Synaptic biomarkers normalize later than amyloid markers following effective treatment
Supports
Combined biomarker panels improve cessation decision confidence in current trials
Contradicts
Neurogranin normalizes more slowly than p-tau217 in treatment studies; requiring co-normalization would extend treatment unnecessarily
Contradicts
Synaptic damage and tau pathology have independent pathological drivers; dissociation may occur without therapeutic failure
Contradicts
No established cessation threshold for neurogranin exists; requirement lacks operational definition
Contradicts
Neurogranin may not normalize even with effective amyloid clearance if irreversible synaptic loss has occurred
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NRGN
No curated PDB or AlphaFold mapping for NRGN yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NRGN, SNAP25 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NRGN, SNAP25.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1902
Events (7d)
1
Price History
▲6.3%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we compute a composite synaptic-health z-score (weighted average of p-tau217 and neurogranin z-scores) from serial CSF measurements in amyloid-positive individuals receiving anti-amyloid therapy, T | Composite synaptic-health z-score accounts for ≥20% greater variance (R² increment ≥0.20) in 24-month CDR-SB change compared to p-tau217 z-score alone | — no observation — | pending | 0.65 |
| IF neurogranin normalizes to baseline reference ranges at least 6 months after p-tau217 achieves normalization in anti-amyloid-treated amyloid-positive participants, THEN the time-to-neurogranin-norma | Spearman correlation ρ ≥ 0.40 between months-to-neurogranin-normalization and months-from-treatment-to-cognitive-trajectory-inflection, with neurogranin normali | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we compute a composite synaptic-health z-score (weighted average of p-tau217 and neurogranin z-scores) from serial CSF measurements in amyloid-positive individuals receiving anti-amyloid therapy, THEN this composite score will explain at least 20% more variance in 24-month longitudinal cognitive
Predicted outcome: Composite synaptic-health z-score accounts for ≥20% greater variance (R² increment ≥0.20) in 24-month CDR-SB change compared to p-tau217 z-score alone
Falsification: Composite score explains <20% greater variance (R² increment <0.20) than p-tau217 alone; OR composite score performance is equivalent or inferior to p-tau217 alone (within 5% margin)
pendingconf 55%
IF neurogranin normalizes to baseline reference ranges at least 6 months after p-tau217 achieves normalization in anti-amyloid-treated amyloid-positive participants, THEN the time-to-neurogranin-normalization will positively correlate with the duration of the critical window for ongoing amyloid-indu
Predicted outcome: Spearman correlation ρ ≥ 0.40 between months-to-neurogranin-normalization and months-from-treatment-to-cognitive-trajectory-inflection, with neurogran
Falsification: Neurogranin normalizes simultaneously with or before p-tau217 (i.e., within 3 months); OR no significant correlation (ρ < 0.40, p > 0.05) exists between normalization timing and cognitive trajectory i
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.